BACTROBAN OINTMENT 2% ww

국가: 싱가포르

언어: 영어

출처: HSA (Health Sciences Authority)

유효 성분:

MUPIROCIN

제공처:

GLAXOSMITHKLINE PTE LTD

ATC 코드:

D06AX09

복용량:

2% w/w

약제 형태:

OINTMENT

구성:

MUPIROCIN 2% w/w

관리 경로:

TOPICAL

처방전 유형:

Prescription Only

Manufactured by:

SMITHKLINE BEECHAM

승인 상태:

ACTIVE

승인 날짜:

1988-04-29

환자 정보 전단

BACTROBAN OINTMENT
MUPIROCIN FREE ACID
QUALITATIVE AND QUANTITATIVE COMPOSITION
2% w/w mupirocin free acid in a white, translucent, water soluble,
polyethylene glycol
base.
PHARMACEUTICAL FORM
Ointment.
CLINICAL PARTICULARS
INDICATIONS
Bacterial skin infections, e.g. impetigo, folliculitis and
furunculosis.
DOSAGE AND ADMINISTRATION_ _
POPULATIONS
_Adults and Children:_
_BACTROBAN_
should be applied to the affected area 2 to 3 times a day for up to 10
days,
depending on the response.
The area may be covered with a dressing or occluded if desired.
Do not mix with other preparations as there is a risk of dilution,
resulting in a reduction in
the antibacterial activity and potential loss of stability of the
mupirocin in the ointment.
CONTRAINDICATIONS
Hypersensitivity to
_BACTROBAN_
or other ointments containing polyethylene glycol and
any of its constituents.
WARNINGS AND PRECAUTIONS
In the rare event of a possible sensitisation reaction or severe local
irritation occurring
with the use of the product, treatment should be discontinued, the
product should be
wiped off and appropriate alternative therapy for the infection
instituted.
As with other antibacterial products, prolonged use may result in
overgrowth of non-
susceptible organisms.
Pseudomembranous colitis has been reported with the use of antibiotics
and may range in
severity from mild to life-threatening. Therefore, it is important to
consider its diagnosis
in patients who develop diarrhoea during or after antibiotic use.
Although this is less
likely to occur with topically applied mupirocin, if prolonged or
significant diarrhoea
occurs or the patient experiences abdominal cramps, treatment should
be discontinued
immediately and the patient investigated further.
This
_BACTROBAN_
ointment formulation is not suitable for
-
ophthalmic use,
-
intranasal use,
-
use in conjunction with cannulae and
-
at the site of central venous cannulation.
Avoid contact with the eyes. If contaminated, the eyes should be
thoroughly irrigated with
water until the ointment residu

제품 특성 요약

BACTROBAN OINTMENT
MUPIROCIN FREE ACID
QUALITATIVE AND QUANTITATIVE COMPOSITION
2% w/w mupirocin free acid in a white, translucent, water soluble,
polyethylene glycol
base.
PHARMACEUTICAL FORM
Ointment.
CLINICAL PARTICULARS
INDICATIONS
Bacterial skin infections, e.g. impetigo, folliculitis and
furunculosis.
DOSAGE AND ADMINISTRATION_ _
POPULATIONS
_Adults and Children:_
_BACTROBAN_
should be applied to the affected area 2 to 3 times a day for up to 10
days,
depending on the response.
The area may be covered with a dressing or occluded if desired.
Do not mix with other preparations as there is a risk of dilution,
resulting in a reduction in
the antibacterial activity and potential loss of stability of the
mupirocin in the ointment.
CONTRAINDICATIONS
Hypersensitivity to
_BACTROBAN_
or other ointments containing polyethylene glycol and
any of its constituents.
WARNINGS AND PRECAUTIONS
In the rare event of a possible sensitisation reaction or severe local
irritation occurring
with the use of the product, treatment should be discontinued, the
product should be
wiped off and appropriate alternative therapy for the infection
instituted.
As with other antibacterial products, prolonged use may result in
overgrowth of non-
susceptible organisms.
Pseudomembranous colitis has been reported with the use of antibiotics
and may range in
severity from mild to life-threatening. Therefore, it is important to
consider its diagnosis
in patients who develop diarrhoea during or after antibiotic use.
Although this is less
likely to occur with topically applied mupirocin, if prolonged or
significant diarrhoea
occurs or the patient experiences abdominal cramps, treatment should
be discontinued
immediately and the patient investigated further.
This
_BACTROBAN_
ointment formulation is not suitable for
-
ophthalmic use,
-
intranasal use,
-
use in conjunction with cannulae and
-
at the site of central venous cannulation.
Avoid contact with the eyes. If contaminated, the eyes should be
thoroughly irrigated with
water until the ointment residu